LAG3 and melanoma: Currently approved ICIs for patients with melanoma are as follows: (Gocher et al., 2022[39]) anti-programmed death 1 (PD-1) antibodies nivolumab and pembrolizumab, anti-PD-L1 atezolizumab (Mendoza et al., 2019[76]), anti- cytotoxic t-lymphocyte-associated protein 4 (CTLA-4) lpilimumab (Ding et al., 2022[27]), and anti-lymphocyte activation gene 3 (LAG-3) relatlimab.